Novartis AG (XTER:NOT) Tariff Resilience Score: 8/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:NOT Novartis AG XTER:NOT
78 GF Score
Price €134.60
GF Value €112.95
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG Tariff Resilience Score?

Novartis AG XTER:NOT 78 Tariff Resilience Score is 8 as of Jul. 14, 2026. GuruFocus rates XTER:NOT with a GF Score™ of 78/100 and a GF Value™ of €112.95 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Novartis AG ranks better than 99.61% on this metric.

Novartis AG has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Novartis AG has Novartis, a global pharmaceutical giant, has a robust supply chain and significant pricing power. Its essential healthcare products often receive tariff exemptions, making it highly resilient to trade policy changes.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Novartis AG might have Highly Resilient.

Novartis AG  (XTER:NOT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Novartis AG Tariff Resilience Score Related Terms

XTER:NOT vs LLY, JNJ, ABBV: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novartis AG Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Novartis AG's Tariff Resilience Score falls into.


XTER:NOT
78GF Score
Novartis AG XTER:NOT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Novartis AG (XTER:NOT) has a Tariff Resilience Score of 8 as of Jul. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Novartis AG ranks #4 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Novartis AG's Tariff Resilience Score too high?
Novartis AG's current Tariff Resilience Score is 8. Based on the distribution chart, Novartis AG ranks #4 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novartis AG has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Tariff Resilience Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novartis AG ranks #4 out of 1029 companies for Tariff Resilience Score. This places Novartis AG in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Novartis AG's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (XTER:NOT) is currently considered Modestly Overvalued. The stock's GF Value™ is €112.95, compared to a current price of €134.60 — trading 19.2% above its estimated fair value. The current Tariff Resilience Score is 8. Novartis AG's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Novartis AG (XTER:NOT), the current Tariff Resilience Score is 8 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (XTER:NOT) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €134.60 is trading 19.2% above its estimated GF Value™ of €112.95. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for XTER:NOT:

  • Tariff Resilience Score: 8
  • GF Value™: €112.95 vs. price of €134.60 (19.2% above fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the XTER:NOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
78GF Score

Get the complete analysis for XTER:NOT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€134.60
Price
€112.95
GF Value